12/07/06

BioTime Announces a Phase II Clinical Trial of Hextend(R) in Japan

11/15/06

BioTime Announces Results for Third Quarter 2006

8/16/06

BioTime Announces Results for Second Quarter 2006

5/16/06

BioTime Announces Results for First Quarter 2006

4/18/06

BioTime Announces Fourth Quarter and Fiscal Year-End Results

4/14/06

Company Profile for BioTime, Inc.

4/10/06

BioTime Announces License Agreement for China and Taiwan

12/22/05

BioTime Raises $1,787,145 in Rights Offer

12/20/05

BioTime Announces Sublicense Arrangement for Japan with Maruishi Pharmaceutical Co., Ltd.

11/29/05

BioTime Amends Terms of Subscription Rights Offer

11/15/05

BioTime Announces Results for Third Quarter 2005

10/27/05

BioTime Commences Rights Offer

09/1/05

BioTime Plans Rights Offering Backed by Standby Guaranty

08/16/05

BioTime Announces Results for Second Quarter 2005

07/14/05

BioTime Announces New Trading Symbols

07/12/05

BioTime Announces New Patent in China

06/20/05

BioTime Moves to New Headquarters

05/17/05

BioTime Announces Results for First Quarter 2005

11/16/04

BioTime Announces Third Quarter Results

8/13/04

Valeta A. Gregg, Ph.D., J.D. Joins BioTime, Inc. Board Of Directors

8/13/04

Biotime Announces Increased Revenues For Second Quarter 2004

7/7/04

BioTime Announces Regulatory Approval of Hextend(R) in South Korea; Receives Second License Fee From CJ Corp.

6/1/04

BioTime Appoints Jeffrey Nickel, Ph.D. Vice President of Business Development and Marketing

5/13/04

BioTime Announces Strong Royalty Revenue Increase for First Quarter 2004

4/21/04

BioTime Awarded NIH Grant to Aid HetaCool Development

2/11/04

BioTime Announces Repayment Of Debentures; Eliminates All Long-Term Debt

1/22/04

BioTime Completes Rights Offer, Announces That Rights Offer Was Heavily Oversubscribed

1/13/04

BioTime Rights Offer Extended to January 21, 2004

1/6/04

BioTime Further Extends Expiration Date of Subscription Rights Offer

12/29/03

BioTime Extends Expiration Date of Subscription Rights Offer

12/11/03

BioTime Commences Rights Offer

10/2/03

BioTime Plans Rights Offering Backed by Standby Guaranty

6/26/03

BioTime Creates Office of the President

6/23/03

BioTime Mourns Passing of Founder

6/4/03

BioTime Meets With Its Industry Partners in Asia

4/14/03

CJ Corp. and BioTime Sign a License Agreement for Korea

12/31/02

Asia-Based Multinationals to Help with BioTime's Overseas Expansion

10/1/02

Dr. Michael D. West Nominated to Join BioTime's Board of Directors

8/13/02

BioTime Raises Over $2 Million in a Private Placement as Quarterly Revenues Grow

7/09/02

Hextend Approved for Sale in Canada

6/26/01

Dr. Katherine Gordon to Join BioTime's Board of Directors

8/30/00

BioTime Successfully Completes Pentalyte Phase I Clinical Trial; Hextend Used to Treat Hypovolemia in Cold Surgical Procedures

4/18/00

BioTime to Begin Clinical Studies of PentaLyte, a New Blood Plasma Volume Expander

4/17/00

Ice-Cold Blood-Substituted Dogs And Hamsters Revived After Prolonged Periods Of Clinical Death; Results May Hold Clues To Protecting The Brain

1/11/00

NPBI Manufactures BioTime's HextendŽ For European Approval

11/10/99

BioTime Endows Study of Aging and Low Temperature Medicine At UC Berkeley and the Lawrence Berkeley National Laboratory

8/30/99

BioTime, Inc. moving from NASDAQ to the American Stock Exchange, Symbol Changes to "BTX"

8/6/99

Abbott Labs News: Hextend® Now Available for the Treatment of Hypovoloemia

7/30/99

Lawrence Berkeley National Lab News: Lab Scientists to Participate in Program to Study Aging

3/31/99

BioTime Receives FDA Approval To Market HextendŽ

3/24/99

BioTime Announces Allocation of Over-Subscription Shares Sold in Rights Offer

3/11/99

BioTime Raises Over $7.3 Million in Rights Offer; Announces That Rights Offer was Heavily Over-Subscribed

2/12/99

BioTime Commences Rights Offer

12/18/98

BioTime Files For Rights Offering

11/20/98

FDA Completes Review Of BioTime's New Drug Application For Hextend®, BioTime Pleased With Quick Response

4/29/98

BioTime Shares Begin Trading On Nasdaq National Market

3/31/98

BioTime Completes Hextend® New Drug Application

2/11/98

Milton Dresner Joins BioTime Board

1/6/98

BioTime and Nihon Sign Letter of Intent

12/18/97

BioTime Initiates New Drug Application Filing For Hextend®

10/31/97

BioTime Announces New President

10/01/97

Pivotal Phase III Clinical Trial Surgeries Completed In BioTime's Hextend® Study; BioTime Shares To Split Three For One

07/21/97

BioTime Receives $1.4 Million In Payments From Abbott Laboratories

07/17/97

BioTime Begins European Hextend Clinical Trials

02/05/97

BioTime Raises Over $5.6 Million in Rights Offering; Rights Offering Heavily Over-Subscribed

01/13/97

BioTime Commences Rights Offering

12/05/96

BioTime to Raise $3,000,000 to $6,000,000 in Rights Offering

10/31/96

BioTime begins Phase III clinical trials of Hextend®

08/19/96

BioTime's Hextend® cleared for Phase III clinical trials

09/24/96

Howard Stein, Former Chairman of Dreyfus Corp., to Advise BioTime

05/01/96

BioTime products, Hextend® and PentaLyte, presented at medical and scientific meetings

04/02/96

BioTime to optimize Hextend® clinical trial protocol

03/01/96

BioTime files Phase III Investigational New Drug Application for Hextend®